Ranibizumab (Lucentis) Intravitreal Injection from Japan
Ranibizumab (Lucentis) is a humanized monoclonal antibody fragment that inhibits VEGF, used for treating wet age-related macular degeneration (AMD). It is presented as an intravitreal injection in measured doses for retail sale, qualifying under tariff item 3002.15.00 as an immunological product. This product regulates angiogenesis through immunological mechanisms.
Duty Rate — Japan → Canada
0%
Import Tips
• Ensure the injection is in retail packaging with measured doses
• Provide batch records and certificates of analysis for customs
• Verify if a Health Canada authorization is needed before import